Trevi Therapeutics, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2018 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Trevi Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2018 to Q1 2024.
  • Trevi Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was -$28K, a 98.4% increase year-over-year.
  • Trevi Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was -$7.91M, a 107% decline from 2022.
  • Trevi Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $111M, a 436% increase from 2021.
  • Trevi Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $20.8M, a 24.3% increase from 2020.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$28K +$1.68M +98.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q1 2023 -$1.7M -$1.08M -172% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q1 2022 -$625K -$4.77M -115% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q1 2021 $4.15M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q1 2019 $9.85M +$11.9M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q1 2018 -$2.05M Jan 1, 2018 Mar 31, 2018 10-Q 2019-06-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.